Skip Navigation


JAC Advance Access originally published online on May 24, 2005
Journal of Antimicrobial Chemotherapy 2005 56(1):110-114; doi:10.1093/jac/dki164
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
56/1/110    most recent
dki164v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (2)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Murray, A.
Right arrow Articles by Brown, D. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Murray, A.
Right arrow Articles by Brown, D. J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2005. Published by Oxford University Press on behalf of the British Society for Antimicrobial Chemotherapy. All rights reserved. For Permissions, please e-mail: journals.permissions@oupjournals.org

Ciprofloxacin resistance in non-typhoidal Salmonella serotypes in Scotland, 1993–2003

A. Murray, J. E. Coia, H. Mather and D. J. Brown*

Scottish Salmonella Reference Laboratory, Stobhill Hospital, 133 Balornock Road, Glasgow G21 3UW, UK

Received 27 October 2004; returned 2 February 2005; revised 18 March 2005; accepted 20 April 2005

* Corresponding author. Tel: +44-141-201-3020; Fax: +44-141-558-5508; E-mail: Derek.Brown{at}northglasgow.scot.nhs.uk

Objectives: To determine the levels of resistance to ciprofloxacin among non-typhoidal salmonellae in Scotland.

Methods: Etest strips were used to determine the ciprofloxacin MICs for nalidixic acid-resistant salmonellae isolated from humans during 1993–2003.

Results: The percentage of nalidixic acid-resistant salmonellae isolated from human infection in Scotland has increased from 1.4% in 1993, to 8.8% in 1998 and 21.3% in 2003. Of 493 strains of nalidixic acid-resistant Salmonella tested, a single isolate of Salmonella Typhimurium RDNC was resistant to ciprofloxacin at the NCCLS breakpoint of 4 mg/L. Eleven isolates were resistant at the Scottish Salmonella Reference Laboratory breakpoint of 0.5 mg/L, while 466 isolates (94.5%) had reduced susceptibility with MICs of ≥0.125 mg/L and <0.5 mg/L.

Conclusions: These results show that very few non-typhoidal isolates of Salmonella in Scotland that are resistant to nalidixic acid are also resistant to ciprofloxacin at the NCCLS recommended breakpoint of 4 mg/L. The majority of isolates examined, however, do show reduced susceptibility at 0.125 mg/L. This confirms the necessity for continuing antimicrobial surveillance of resistance to this important antibiotic.

Keywords: resistance surveillance , fluoroquinolones , Etest


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 J. Clin. Microbiol.Home page
F.-X. Weill, F. Guesnier, V. Guibert, M. Timinouni, M. Demartin, L. Polomack, and P. A. D. Grimont
Multidrug Resistance in Salmonella enterica Serotype Typhimurium from Humans in France (1993 to 2003).
J. Clin. Microbiol., March 1, 2006; 44(3): 700 - 708.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.